GlassScriptPhysician profile
Natalie R Dickson
NPI 1700839263
$5,800.52
in general payments reported to CMS, 2019-2025
37 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,084 · 2020: $244 · 2021: $11.92 · 2022: $260 · 2023: $338 · 2024: $214 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $1,297.96 | 2019-2020 | |
| Celgene Corporation | $1,182.11 | 2019-2025 | Reblozyl |
| Abbvie INC. | $756.08 | 2019-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $473.90 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $285.59 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $221.68 | 2019-2024 | Opdivo |
| Daiichi Sankyo INC. | $152.08 | 2024-2025 | Enhertu |
| Astellas Pharma US INC | $148.33 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Foundation Medicine, INC. | $134.10 | 2020-2022 | |
| Stemline Therapeutics INC. | $119.16 | 2025 | Orserdu |
| Pfizer INC. | $88.96 | 2019-2025 | |
| Amgen INC. | $81.04 | 2022 | |
| Janssen Biotech, INC. | $80.52 | 2019-2025 | Darzalex, Tecvayli |
| Gilead Sciences, INC. | $70.36 | 2019-2023 | |
| Eisai INC. | $67.66 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $63.13 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.04 | 2019-2022 | |
| Adc Therapeutics America, INC. | $57.31 | 2024-2025 | |
| Emd Serono, INC. | $50.13 | 2019-2020 | |
| Genzyme Corporation | $45.78 | 2019-2020 | |
| Seagen INC. | $40.42 | 2019-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $37.71 | 2019-2023 | Imbruvica |
| Lexicon Pharmaceuticals, INC. | $31.79 | 2019 | |
| Incyte Corporation | $25.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.40 | 2023 | Ultomiris |
| Iovance Biotherapeutics, INC. | $24.12 | 2025 | Amtagvi |
| Tolmar Pharmaceuticals, INC. | $20.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Array Biopharma INC | $20.02 | 2019 | |
| Deciphera Pharmaceuticals INC. | $18.51 | 2024 | Qinlock |
| Teva Pharmaceuticals USA, INC. | $16.83 | 2019 | |
| Cti Biopharma Corp. | $16.52 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $16.48 | 2020 | |
| Rigel Pharmaceuticals, INC. | $14.15 | 2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $13.47 | 2019 | |
| Lilly USA, LLC | $12.87 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.